Company Overview
PepGen Inc. operates as a clinical-stage biotechnology entity focused on the United States market, specifically developing oligonucleotide therapeutics designed to treat severe neuromuscular and neurologic diseases. The company is currently engaged in the advancement of PGN-EDODM1, an EDO peptide-conjugated PMO, which has progressed into a Phase 2 clinical trial stage. This business model places the organization within the broader Healthcare sector and the specialized Biotechnology industry, where success is contingent upon the progression of clinical data and regulatory approval pathways rather than established commercial sales. As of the latest available data, the company carries a market capitalization of $337.28M and employs a workforce of 56 individuals. The combination of a market cap exceeding $300 million with a relatively small employee base of 56 suggests a capital-intensive R&D phase where the value is derived from intellectual property and pipeline assets rather than current operational scale or revenue generation.
Financial Health
The company's financial statements for the trailing twelve months reflect a net income of $-89,655,000 and an EBITDA of $-92,215,000, while revenue figures are not available in the current dataset. The substantial gap between the reported net income and the EBITDA indicates that non-operating expenses or financing costs, rather than core operational inefficiencies, are the primary drivers of the company's negative bottom line. Free cash flow stands at $-49,845,500, which signifies that the company is consuming cash to fund its development activities and lacks the immediate financial flexibility to cover capital expenditures without external funding. The company holds $148.46M in cash and cash equivalents against a total debt obligation of $17.00M, resulting in a debt-to-equity ratio of 11.53. Although the absolute debt level is low relative to cash reserves, the elevated debt-to-equity ratio of 11.53 mathematically implies a highly leveraged capital structure in traditional accounting terms, though the positive net cash position mitigates immediate solvency risks. The margins for the company are all reported as 0.0% for gross, operating, and profit categories, which is consistent with a pre-revenue biotechnology firm that has not yet generated commercial sales to calculate profitability percentages. Liquidity is robust, evidenced by a current ratio of 11.94, which indicates that the company possesses more than eleven times the current assets necessary to cover its short-term liabilities. Return on Equity is recorded at -67.4% and Return on Assets at -36.0%, metrics that reveal that management is currently utilizing shareholder and asset bases to generate losses rather than profits, a common characteristic for clinical-stage firms investing heavily in research.
Valuation Assessment
Valuation multiples for PepGen Inc. present a mixed picture due to the lack of positive earnings, with the P/E Ratio (TTM) listed as N/A and the Forward P/E calculated at -3.99. The existence of a negative forward P/E implies that analysts or the market is pricing the stock based on expected future earnings that may eventually turn positive, or it reflects the current inability to value the stock using traditional earnings-based metrics. The price-to-book ratio is 2.28, suggesting that the market values the company at a premium of roughly 128% over its book value, a premium often justified by the potential value of the Phase 2 pipeline assets. Alternative valuation metrics such as the price-to-sales ratio are unavailable (N/A), and the EV/EBITDA stands at -2.23, further indicating that earnings-based valuation methods are not currently applicable due to negative earnings. The stock's recent trading range is defined by a 52-week high of $7.80 and a 52-week low of $0.88. Without the current price explicitly listed in the provided facts to calculate a precise percentage, the valuation context is strictly defined by this wide trading range of $6.92. The beta of 1.87 indicates that the stock is expected to be significantly more volatile than the broader market, moving with an intensity that is 87% higher than the market average during periods of fluctuation.
Growth & Income
Growth metrics for PepGen Inc. are unavailable for the trailing twelve months, with Revenue Growth (YoY) and Earnings Growth (YoY) both listed as N/A. The absence of positive revenue prevents a direct comparison of earnings growth versus revenue growth, as the company has not yet reached a stage where commercial sales are the primary performance indicator. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Since the company does not distribute income to shareholders, the 0.0% payout ratio is not a sustainability concern but rather a reflection of the strategy to reinvest all available capital, including the $148.46M cash on hand, back into the clinical development of oligonucleotide therapeutics. The overall growth and income profile is characterized by a reliance on future clinical milestones rather than current financial performance or income distribution to existing shareholders.